HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators.

Abstract
Evaluation of cell cycle regulators has gained special interest in the effort to increase the amount of prognostic information in malignant tumors. Minichromosome maintenance proteins (MCMs) drive the formation of prereplicative complexes, which is the first key event during G1 phase. Therefore, altered MCM expression may be a hallmark of cell cycle deregulation, which is supposed to be the most essential mechanism in the development and progression of bladder cancer. Our aim was to investigate the value of MCMs as proliferation markers and prognostic indicators in detrusor muscle-invasive urothelial bladder carcinomas. We analyzed immunohistochemically the expression of MCM-2 and MCM-5 in 65 patients with detrusor muscle-invasive urothelial bladder carcinomas in relation with clinicopathologic parameters, patients' overall and disease-free survival, and the expression of the conventional proliferation index Ki-67 and other cell cycle modulators (p53, pRb, p21(WAF1), and p27(Kip1)). The levels of MCM-2 and MCM-5 were significantly higher in high-grade (P < .0001), advanced-stage (P = .001), and nonpapillary tumors (P < .0001). The expression of MCM-2 and MCM-5 significantly associated with the conventional proliferation index Ki-67 (P = .0001 for each protein). The expression of MCM-2 or MCM-5 positively correlated with p53 labeling index (P = .014 and P = .009, respectively). Also, median p21(WAF1) labeling index was higher in MCM-5 high expressors (P = .028). Finally, both MCM-2 and MCM-5 associated significantly with adverse patients' outcome in both univariate (P = .0072 and P = .0074, respectively) and multivariate (P = .0001) analysis. In conclusion, MCM-2 and MCM-5 appear to be reliable proliferation indexes and useful prognostic markers in patients with muscle-invasive urothelial bladder carcinomas.
AuthorsPenelope Korkolopoulou, Nikolaos Givalos, Angelica Saetta, Athina Goudopoulou, Hariklia Gakiopoulou, Irene Thymara, Euphemia Thomas-Tsagli, Efstratios Patsouris
JournalHuman pathology (Hum Pathol) Vol. 36 Issue 8 Pg. 899-907 (Aug 2005) ISSN: 0046-8177 [Print] United States
PMID16112007 (Publication Type: Journal Article)
Chemical References
  • Biomarkers, Tumor
  • CDKN1A protein, human
  • Cell Cycle Proteins
  • Cyclin-Dependent Kinase Inhibitor p21
  • DNA-Binding Proteins
  • Ki-67 Antigen
  • Schizosaccharomyces pombe Proteins
  • Tumor Suppressor Protein p53
  • Tumor Suppressor Proteins
  • mcm5 protein, S pombe
  • Cyclin-Dependent Kinase Inhibitor p27
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor (analysis)
  • Carcinoma, Transitional Cell (metabolism, pathology)
  • Cell Cycle Proteins (biosynthesis)
  • Cyclin-Dependent Kinase Inhibitor p21
  • Cyclin-Dependent Kinase Inhibitor p27
  • DNA-Binding Proteins (biosynthesis)
  • Female
  • Humans
  • Immunohistochemistry
  • Ki-67 Antigen (metabolism)
  • Male
  • Middle Aged
  • Muscle Neoplasms (metabolism, mortality, secondary)
  • Prognosis
  • Retrospective Studies
  • Schizosaccharomyces pombe Proteins (biosynthesis)
  • Survival Analysis
  • Survival Rate
  • Tumor Suppressor Protein p53 (biosynthesis)
  • Tumor Suppressor Proteins (biosynthesis)
  • Urinary Bladder Neoplasms (metabolism, mortality, pathology)
  • Urothelium (metabolism, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: